Health Kick Podcast: Aroa Biosurgery reaches path to profitability

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim chats with Aroa Biosurgery (ASX:ARX)  chief financial officer James Agnew about the company’s full year financials for FY25.

Headquartered in New Zealand, Aroa Biosurgery is unlocking regenerative healing with a range of products based on its AROA ECM™ platform technology.

The company reported significant growth this past financial year, with 23% grown on FY24.

Revenue was up to NZ$84.7 million, exceeding the company’s guidance of NZ$81 – 84 million.

The gross product margin also grew to 86%,  with AROA direct sales accounted for 53% of the product revenue mix, and its Myriad technology expected to continue to become a larger part of the overall sales mix.

Listen in to the podcast to hear more about Aroa’s future plans.

This podcast was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.